Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603863 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00603863 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 80 participants.
The verdict
NCT00603863, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a study to test whether different doses of 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.
Interventions
- BIOLOGICAL IMMU-107 (hPAM4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603863
The ClinicalTrials.gov registry entry for NCT00603863 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMMU-107 (hPAM4) is the first listed.
NCT00603863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603863 about?
NCT00603863 is a clinical study titled "Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer". This is a study to test whether different doses of 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.
What is the current status of trial NCT00603863?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2008-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00603863?
The interventions under investigation include: IMMU-107 (hPAM4) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00603863?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.